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Abstract
Background: Comprehensive understanding of cellular immune subsets involved in regulation of tumor
progression is central to the development of cancer immunotherapies. Single cell immunophenotyping has
historically been accomplished by flow cytometry (FC) analysis, enabling the analysis of up to 18 markers. Recent
advancements in mass cytometry (MC) have facilitated detection of over 50 markers, utilizing high resolving power
of mass spectrometry (MS). This study examined an analytical and operational feasibility of MC for an in-depth
immunophenotyping analysis of the tumor microenvironment, using the commercial CyTOF™ instrument, and
further interrogated challenges in managing the integrity of tumor specimens.
Results: Initial longitudinal studies with frozen peripheral blood mononuclear cells (PBMCs) showed minimal MC
inter-assay variability over nine independent runs. In addition, detection of common leukocyte lineage markers
using MC and FC detection confirmed that these methodologies are comparable in cell subset identification. An
advanced multiparametric MC analysis of 39 total markers enabled a comprehensive evaluation of cell surface
marker expression in fresh and cryopreserved tumor samples. This comparative analysis revealed significant
reduction of expression levels of multiple markers upon cryopreservation. Most notably myeloid derived suppressor
cells (MDSC), defined by co-expression of CD66b+ and CD15+, HLA-DRdim and CD14− phenotype, were
undetectable in frozen samples.
Conclusion: These results suggest that optimization and evaluation of cryopreservation protocols is necessary for
accurate biomarker discovery in frozen tumor specimens.
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Background
Cancer represents a multifaceted disease characterized
not only by extreme genetic and epigenetic heterogeneity
of the transformed cells, but also by clonal progression of
treatment-resistant tumors as a result of targeted therap-
ies. In addition to molecular resistance, tumor-mediated
suppression of the self-immune system is thought to
contribute to tumor evasion from effector cells [1]. Early
efforts to modulate immune system’s anti-tumor
functionality has resulted in only marginal therapeutic ef-
ficacy [2, 3]. However, to date, more than 10 antibody
(Ab)-based therapies are available in the clinic [4]. Most
recent are targeting two immuno-checkpoint receptors;
CTLA4 (cytotoxic T-lymphocyte-antigen 4), PD-1
(programmed cell death 1) and its ligand PDL1, and
show a remarkable efficacy against certain tumors,
through re-activating cytotoxic T (Tc) cell mediated
tumor killing [5, 6]. These positive clinical outcomes
support further investment in targeting additional im-
munomodulatory receptors on T-cytotoxic (Tc) cells,
and expanding these approaches to other immune
cells. For example natural killer (NK) cells can be re-
cruited to kill tumor cells, without potential concern
for causing acute cytokine storm or long-term auto-
immune responses [7, 8], while suppression of T-
regulatory (Treg) cells can be used to enhance
immune response against tumor cells [9].
In order to accelerate the delivery of immunomodu-
lators from the bench to the bedside, it is imperative to
have a toolbox of biomarkers that can be used for in-
depth understanding of the complexity of disease-
underlying biology, and refine translational validity be-
tween preclinical efficacy and the highly diverse patient
response [10–12]. To address this, a greater emphasis
on the use of clinical specimens for discovery of dis-
ease relevant biomarkers has been placed for diagnosis,
prognosis, assessment of treatment efficacy and patient
stratification strategies [13, 14]. Today, the collection
of patient samples, such as core-needle biopsies and
blood, for genetic and other analyses has become com-
mon practice, offering accurate determinations from
limited clinical tissues [15]. However, effective bioana-
lytical tools that encompass complex immune- and
tumor cells interactions in a clinical trial setting have
been lacking [16, 17].
For the past several decades multiparametric fluores-
cent cytometry has been used in research and clinical
laboratories to significantly advance biomarker discovery
by immunophenotyping highly heterogeneous tumor
samples [18–20]. However due to spectral overlap of
fluorophore conjugated to detection antibodies, and in-
herent high sample auto-fluorescence, practical
detection is currently limited to 12–18 simultaneous in-
dependent markers [21–23]. The recently developed
mass-spectrometry (MS) based technology, or com-
monly referred to as cytometry by time-of-flight
(CyTOF™), has enabled multiplexed cellular analysis of
up to 100 parameters. Mass cytometry has overcome
many limitations seen with FC, by utilizing metal conju-
gated antibodies coupled with atomic MS detection [24].
The use of rare-earth transitional metals as detection
tags provides a clear advantage over fluorescent labels as
these are not naturally occurring within the human
body, and the added advantage of MS resolution capabil-
ities of single mass differences, allows for quantification
of signals without cellular background interference or
significant signal spillover, thus making CyTOF™ well
suited to for multi-dimensional single cell analysis of
limited clinical specimens [25, 26]. Furthermore, integra-
tion of highly multiplexed detection on a single cell level
with an advanced statistical analysis allows for the un-
biased delineation of the cellular subsets that can be eas-
ily overlooked by trying to assemble several detection
Ab panels utilized by flow cytometry [27]. In the short
period of time since the introduction of this technology
several break-through studies demonstrated the potential
of this platform to interrogate complex mechanistic and
biomarker networks [28–30]. Moreover, recent studies
of tumor samples demonstrated that MC could greatly
improve knowledge of the complex cellular milieu of
acute myeloid leukemia (AML) by utilizing 35–40 simul-
taneous detection markers [31]. While findings like these
have highlighted the advanced analytic capabilities of
MC, the use of this platform to develop a fit-for-purpose
immunophenotyping analysis of tumor specimens from
clinical trials remain to be evaluated in the context of
clinical sample handling logistics.
In this study, MC detection stability was first evaluated
by nine independent experimental runs of a well-
characterized single PBMC lot utilizing 14 cell surface
markers. After establishing optimized MC throughput,
detection and data analysis protocols, we expanded on
previous publications [32, 33] by further validating ap-
plicability of the comprehensive immunophenotyping of
PBMCs and clinical tumor samples as compared to mea-
surements obtained using conventional FC. The cumula-
tive findings of these studies confirmed that the CyTOF™
platform supports comprehensive multiparametric bio-
marker discovery, as evidenced by the analysis of 39
simultaneously detected markers.
While assessing accuracy of the high multiparametric
analytical potential of MC detection, this study further
evaluated the impact of cryopreservation on the immune
cell markers by comparing fresh and subsequently cryo-
preserved human tumor specimens. Due to concerns
about clinical sample stability during shipment and in an
effort to standardize analysis conditions across many
specimens, the samples are commonly cryopreserved
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shortly after collection [34], and analyzed at a later time
as a single batch to minimize technical and systems vari-
ability. However recent publications have raised ques-
tions about sample integrity and reliability of these
specimens [35, 36]. Results of our study showed a sig-
nificant reduction in expression levels of most myeloid
markers such as CD11B, CD14, CD15, CD16, CD66,
CD86, CD80, and CD56 as well as immunoregulatory re-
ceptors (IMRs) upon cryopreservation. Most notable
was the complete loss of detection of myeloid derived
suppressor cells (MDSC). These results strongly caution
the use of cryopreserved tumor samples for biomarker
discovery and merit further studies to identify advanced
cryopreservation protocols.
Methods
Fluorescent and mass cytometry detection antibodies
Sample sourcing
PBMCs were purchased from SeraCare Life Sciences Inc.,
(Milford, MA). Frozen dissociated tumor cells (DTC) and
normal adjacent tissue (NAT) were purchased from Con-
versantBio (Huntsville, AL). The frozen samples were
shipped on dry ice and stored in liquid nitrogen. Dissoci-
ation and cryopreservation of tumor tissue specimens,
resected in 2010 and 2012, were performed by the vendor
by applying tissue specific protocols that employed both
enzymatic and mechanical dissociation. Fresh human
tumor specimens were properly collected with all neces-
sary approvals, consents and/or authorizations for the col-
lection, use and/or transfer of such human tissues through
Neurologica Cognitiva Research LLC DBA Boston Bio-
source (Newton, MA). Tumor samples were stored in
AQIX® media (AQIX LTD, London, UK), a formulation
optimized to maintain pH levels and mimic the intestinal
fluid layer while preserving genetic and histological pro-
files of excised tissue for up to 72 h following removal
from patients [37]. The samples were shipped and stored
at 4 °C, and tissue processing occurred within 12 h of sur-
gical removal.
Frozen sample recovery
Cells were rapidly thawed in a 37 °C water bath, and di-
luted in pre-warmed complete medium: Roswell Park
Memorial Institute (RPMI) 1640 medium supplemented
with 10% fetal bovine serum (FBS), (both LifeSciences,
Carlsbad, CA). Residual dimethyl sulfoxide (DMSO) was
removed by centrifugation at 400 g for 5 min and
pelleted cells were resuspended in growth media and
allowed to recover for 30 min at 37 °C and 5% CO2 prior
to subsequent procedures [38].
Fresh tissue dissociation
Dissociation of fresh renal cell carcinoma and colorectal
tumor tissues was performed according to manufacturer’s
instructions for the human tumor dissociation kit
(Milteny, Auburn, CA); briefly the tissue samples were cut
up into smaller pieces and subjected to enzymatic and
mechanical dissociation using the vendor supplied enzyme
cocktail and the GentleMACS™ dissociator (Miltenyi,
Auburn, CA). The mechanical dissociation protocol
employed variable blade rotation speeds for 60 min at
37 °C. After tissue dissociation, red blood cells (RBC)
were lysed using Ammonium-Chloride-Potassium
(ACK) buffer (Life Sciences, Carlsbad, CA) for 5 min
at RT. The samples were washed twice with complete
medium by pelleting at 400 g for 5 min and the cell
count was determined using Vi-Cell (Beckman
Coulter, Indianapolis, IN). The resulting single sell
suspension was stained for immediate analysis by FC
and MC while residual cells were cryopreserved.
Cryopreservation of dissociated tumor cells (DTC)
The cells were cryopreserved in four different freezing
media at concentrations ranging from 2 × 106 to 5 × 106
cells/mL. The following cryopreservation media (CM)
were tested; CM1: 90% FBS (Gibco, Grand Island, NY)
and 10% DMSO Hybri-Max™ (Sigma-Aldrich, St. Louis,
MO); CM2: 50% AQIX® media, 40% FBS and 10%
DMSO Hybri-Max™; CM3: 90% AQIX media and 10%
UltraPure™ Glycerol (Invitrogen, Carlsbad, CA); CM4:
CryoScarless DMSO-Free media (BioVerde, Kyoto,
Japan). The freezing media was added gently to the cells
and transferred to sterile Nalgene® cryogenic vials
(Sigma-Aldrich, St. Louis, MO). CoolCell® alcohol-free
cell freezing containers (Biocision, San Rafael, CA) were
used to limit rate of freezing to a −1 °C to −3 °C per mi-
nute temperature drop. After 24 h incubation at −70 °C,
the cryovials were transferred to −140 °C liquid nitrogen
for long term storage. Two cryovials from each cryome-
dia formulation were recovered after 28 and 56 days for
immunophenotyping analysis.
Flow cytometry staining and acquisition
Cells were stained for FC via traditional methods. Briefly,
cells were re-suspended in Dulbecco's Phosphate
Buffered Saline (DPBS) (GE Healthcare, Logan, UT) and
stained with cell viability dye (Life Technologies,
Carlsbad, CA) for 15 min on ice. Cells were washed
twice by pelleting at 400 g for 5 min, using standard FC
buffer (1% BSA (w/v) in DPBS). The samples were then
treated with human Fc Block™ (BD Biosciences, Franklin
Lakes, NJ) for 15 min at a concentration of 2.5 μg per 1 ×
106 cells in FC buffer. The samples were washed once,
and incubated for 60 min on ice with the antibody
cocktail prepared in FC buffer. Following incubation the
samples were washed twice with FC buffer and analyzed
using LSR Fortessa SORP (BD Biosciences, Franklin
Lakes, NJ). Compensation was performed using AbC™
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bead kit (Invitrogen, Carlsbad, CA) and fluorescence
minus multiple (FMM) controls were employed to bench-
mark sample background and signal-spillover. A high-
throughput sampler (HTS) module was used for sample
acquisition.
Mass cytometry staining and acquisition
The cells were stained as previously described [28].
Briefly, in preparation for staining with Lanthanide-
conjugated antibodies, the samples were resuspended
and incubated for 30 min at 37 °C with Cell-Staining-
Medium (CSM) and 1X 103Rh DNA Intercalator (both
Fluidigm, San Francisco, CA) at a concentration of 1 ×
106 viable cells/mL. The samples were pelleted by centri-
fugation at 400 g for 5 min at RT and incubated for
20 min at RT with 10 μl of human TruStain FcX™ (Bio-
Legend, San Diego, CA). A mixture of antibodies, using
vendor specified concentrations as well as concentra-
tions determined by single stain titration (data not
shown), in CSM, was added to a final volume of 100 μl/
well. The samples were incubated with staining anti-
bodies for 60 min at 4 °C with gentle vortexing. The
samples were washed twice and incubated for 60 min at
4 °C with Fix/Perm buffer containing 1x 191,193Ir DNA
Intercalator (both Fluidigm, San Francisco, CA), and
then again twice with DPBS and resuspended in Milli-Q®
water (Millipore, Billerica, MA). The samples were ac-
quired using CyTOF™, with upgraded mass channel
range (CyTOF™ 2, Fluidigm, San Francisco, CA), as pre-
viously described [24, 29]. Metal minus multiple
(MMM) control samples were used to define positive
signals and determine spillover, if any. Daily mainten-
ance and tuning was performed according to manufac-
turer’s instructions [39]. In addition to internal vendor-
set calibration procedures, Europium beads were incor-
porated into daily operation before and after sample ana-
lysis, enabling inter-run normalization.
Data analysis
Flow cytometry samples were analyzed using FCS
Express 4 Flow RUO (De Novo Software, Glendale, CA).
CyTOF™ data was analyzed using Cytobank (Cytobank,
Inc., Mountain View, CA) as previously described [40].
Briefly doublets and debris were excluded from analysis
using previously described gating schemes [41], and
manual gating on bivariate plots allowed for identifica-
tion of populations of interest using published pheno-
types [42]. Similarly exclusion of doublets and debris
from FC data was performed using traditional methods
in published literature. Positive signals were identified
using FMM and MMM controls as well as anti-CD3/
CD28 activated PBMCs overexpressing immunoregula-
tory receptors (IMRs) (data not shown). Pearson product
moment correlation (PPMC) was used to compare FC
and MC data sets, with a two tailed p value (GraphPad
Software V.6, La Jolla, CA). The data sets were com-
pared using median intensity values measured for
common antibodies. Non-hierarchical, clustering of
tumor samples was performed using viSNE [43].
Briefly, high-dimensional biological data generated by
mass cytometry is reduced to two dimensions using
the Barnes-Hut implementation of the t-SNE algo-
rithm [44], and visualized as a traditional scatter plot.
Between 10,000 and 40,000 cells were sampled and
live singlet cells were used as the parent population,
subsequent clustering was performed using markers
included in the panel. Expression levels were dis-
played as median intensities in all viSNE plots.
Results
Determination of mass cytometry inter-run
reproducibility
A commercially sourced lot of frozen PBMCs from a
single healthy donor were used to optimize CyTOF™
protocols, and to establish inter-assay variability for
mass cytometry as assessed by measurements of well-
defined immune cell subsets. For all experiments a
total of two-million cells were stained per sample.
Due to cell loss during sample preparation and
CyTOF™ sampling [45], on average 300,000 to 500,000
cells were acquired per run. By adhering to published
guidelines for rare-event analysis [46] we chose to ex-
clude subpopulations consisting of less than 100 cel-
lular events. The gating scheme used to identify
major cellular subsets is shown in Fig. 1a. Dead cells
and doublets were excluded from analysis using previ-
ously described methods for MC and FC [41, 47, 48].
CD45 positive cells were used as the parent popula-
tion for the initial bivariate plot identifying T-cells
(CD3+) and B-cells (CD19+). The T-cell compartment
was further delineated into helper T-cells (CD3 +CD4+)
and cytotoxic T-cells (CD3 + CD8+), whereas B-cell
were identified by co-expression of CD19+ and
CD45RA+. The CD3-CD19- double negative popula-
tion was used to identify monocytes (CD14+) and
NK-cells (CD14-CD16+), while the dendritic cell (DC)
phenotype was characterized by the absence of CD16-
and CD14- expression, and positive co-expression of
CD11c and HLA-DR. The Log10 radial plot (Fig. 1b)
summarizes the distribution of these cellular subsets
across nine independent assays. Average values for
helper-T-cells, cytotoxic-T-cells and NK-cells represented
38.1 ± 3.2, 20.0 ± 3.4 and 16.3% ± 3.1% of CD45+ cells re-
spectively, while B-cells, monocytes and MDCs made up a
smaller fraction of PBMCs with 7.4 ± 2.1, 10.3 ± 2.5 and
4.1% ± 1.0% respectively. This data confirms significant
inter-run correlation using MC detection, across nine in-
dependent runs.
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Comparison of MC and FC for frozen PBMC and DTC
sample analyses
To further confirm accuracy of mass cytometry detec-
tion as compared to flow cytometry, we used the same
lot of frozen PBMCs to compare frequencies of cellular
subtypes, as determined by both detection methods. The
PBMC samples were stained for common cell surface
markers, with clonally matched Abs whenever possible
for both platforms (Table 1). The number of detection
markers was limited to one panel of 15 Abs due to the
FC detection limitations [21]. The percentage of positive
cells on the bivariate plot of CD45+ and markers com-
mon to both platforms was measured in three independ-
ent experiments (Fig. 2a). The results obtained using FC
and MC detection were compared using PPMC analysis
(Fig. 2b), and data indicated a statistically significant
agreement in percentage distributions across both plat-
forms as evident by the correlation coefficient (r) value
of 0.96 (p < 0.0001). These findings are in agreement
with previously published reports indicating comparable
results between fluorescent and mass cytometry for
PBMCs [31, 33].
In order to determine if the correlation between MC
and FC observed in a single donor PBMC lot extends to
significantly more heterogeneous tumor samples, com-
parison experiments were conducted using five frozen
commercial DTCs. Upon thawing cell suspensions were
split for FC and MC analysis, and subsequently further
split into staining and control panels. The frequency of
positive cells was measured on bivariate plots of CD45+
and markers common to both platforms, as detailed in
the gating strategy for PBMC analysis (Fig. 2a). For the
FC analysis, samples were subdivided into four panels;
myeloid, lymphoid and corresponding FMM panels,
while MC samples were split into a control MMM panel,
and a single staining panel. Due to limited sample avail-
ability, only one comparison experiment was feasible for
each tumor sample, with acquired cell numbers ranging
from 13,000 to 500,000 on either platform (Fig. 3b). The
distribution of ratios of percentages of positive cells de-
termined by FC over MC, for each of the 19 common
markers, is summarized in Fig. 3a. The correlation be-
tween FC and MC detection varied between specimens,
with r values ranging from 0.34 to 0.86. The greatest
agreement was observed for the ovarian tumor sample
with frequency distribution within two-fold of each
other, and the corresponding r of 0.86 and p <0.0001
values confirming significant correlation across both de-
tection platforms. The greatest discrepancy in measure-
ments was apparent for the stage I thymus sample, with
the FC/MC ratios of the measured populations being
greater than three-fold, r = 0.34. A detectable difference
in percentage of measured populations was also ob-
served between MC and FC analysis for the lung sample
Fig. 1 Determination of inter-run reproducibility of mass cytometry platform (CyTOF2™). a Representative gating scheme applied to identification
of immune subsets in PBMCs from a single donor. b Longitudinal analysis of major immune subsets in CD45+ cells (N = 9). Data is expressed as
percentage of CD45+ cells on log10 scale
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(r = 0.77), with percentages for CD15, CD86 and GITR
showing between 4 and 6-fold difference in calculated
ratios between platforms.
Further analysis indicated that samples with high
correlation across the two platforms also had a greater
percentage of viable cells, and this correlation was also
significantly better in samples where starting cell num-
bers were similarly detected by both FC and MC
(Fig. 3b). While viability determination by FC employed
amine reactive dyes, which are added prior to fixation and
permeabilization [49], MC utilized two distinct DNA
intercalators; one which is added pror to permeabilazation
(103Rh), and a second DNA intercalator (191/193Ir) which is
added in a buffer containing paraformaldehyde and sap-
onin [50]. Although fixation and permeabilization after
cell surface staining is a standard procedure for immuno-
staining and has minimal consequences to epitope bind-
ing, it is possible that tumor cells, already subjected to en-
zymatic and mechanical dissociation as well as
cryopreservation are more sensitive to membrane effects
imposed by even brief exposures to detergents [51]. Previ-
ous publications comparing FC-based detection of sample
viability and cellular enumeration to other methods, re-
ported that poor specimen quality and low cellularity sam-
ples generally result in inconsistencies across different
methodologies [52, 53]. Thus a combination of both lim-
ited cell numbers available for analysis and the inherent
differences in cell viability determination methodologies
between FC and MC in these samples can partially ac-
count for discrepancies in detected positive cell
percentages.
Validation of multiparametric MC analysis for biomarker
discovery
Consistent results from MC and FC in reproducibility
studies using the same sample indicate that both plat-
forms perform similarly in quantifying common
leukocyte lineage markers in both PBMC and tumor
samples. However, increased multiplexing potential of
the MS detection can significantly facilitate the discovery
of specific immune cell subsets involved in mediating
anti-tumor activity [54, 55]. Applicability of this platform
to biomarker discovery and its translational value was
evaluated next. A representative example of an in-
depth cell population analysis of a fresh renal carcin-
oma (RCC) tumor enabled by MC detection was per-
formed using a 39 surface marker CyTOF™ panel
(Additional file 1). Data in Fig. 4 illustrates median
expression levels of selected surface markers in tumor
infiltrating lymphocytes (TILs) and identifies distinct
subpopulations (Sp) in tumor cells in the RCC sam-
ple. Approximately 40,000 single nucleated cells were
evaluated by a viSNE analysis [43], using CD45,
CD19, CD11B, CD4, CD8A, CD11C, CD34, CD66B,
Table 1 Antibody Panels for Flow and Mass Cytometry Analyses
Antibody Clone Conjugate for detection Vendor
FC MC FC MC FC MC
CD3 UCHT1 UCHT1 BUV737 170Er BD FL
CD4 RPA-T4 RPA-T4 PerCPCy5.5 145Nd BL FL
CD8a RPA-T8 RPA-T8 AF 700 146Nd BL FL
CD11b ICRF44 ICRF44 APC-Cy7 144Nd BL FL
CD11c Bu15 Bu15 AF 488 147Nd BL FL
CD14 HCD14 M5E2 BV 737 160Gd BD FL
CD15 W6D3 W6D3 BV 605 164Dy BD FL
CD16 n/a 3G8 n/a 148Nd n/a FL
CD19 HIB19 HIB19 AF 800 142Nd BL FL
CD25 2A3 2A3 PE 169Tm BD FL
CD27 L128 L128 BV 510 155Gd BD FL
CD33 n/a WM53 n/a 158Gd n/a FL
CD38 n/a HIT2 n/a 167Er n/a FL
CD44 n/a BJ18 n/a 166Er n/a FL
CD45 HI30 HI30 BUV395 154Sm BD FL
CD45RA n/a HI100 n/a 143Nd n/a FL
CD45RO n/a UCHL1 n/a 149Nd n/a FL
CD56 HCD56 HCD56 PE-Cy7 176Yb BL FL
CD62L n/a DREG-56 n/a 153Eu n/a FL
CD66b G10F5 80H3 AF 647 152Sm BD FL
CD66 n/a CD66a-B1.1 n/a 171Yb n/a FL
CD80 L307.4 n/a BV 510 n/a BD n/a
CD86 2331 IT2.2 BV 510 156Gd BD FL
CD107a n/a H4A3 n/a 151Eu n/a FL
CD127 A019D5 A019D5 BV 605 165Ho BL FL
CD152 n/a 14D3 n/a 161Dy n/a FL
CD183 n/a G025H7 n/a 156Gd n/a FL
CD185 n/a 51,505 n/a 171Yb n/a FL
CD194 n/a 205,410 n/a 158Gd n/a FL
CD196 n/a G034E3 n/a 141Pr n/a FL
CD197 n/a G043H7 n/a 159 Tb n/a FL
CD223 n/a 874,501 n/a 150Nd n/a FL
CD273 MIH18 24 F.10C12 BV 711 172Yb BD FL
CD274 29E.2A3 29E.2A3 BV 421 175Lu BL FL
CD279 EH12.2H7 EH12.2H7 BV 786 175Lu BL FL
CD357 621 In-house PE 159 Tb BL FL
TIGIT MBSA45 n/a AF 647 n/a eBio n/a
KI-67 n/a Ki-67 n/a 168Er n/a FL
HLA-DR L243 L243 PerCPCy5.5 174Yb BL FL
HLA-ABC G45-2.6 W6-32 PE-Cy7 141Pr BD FL
FOXP3 259D PCH101 AF 488 162Dy BL FL
The antibodies used in both fluorescent and mass cytometry were
commercially sourced
Abbreviations: MC mass cytometry, FC flow cytometry, AF Alexa Fluor, BV
Brilliant Violet, BUV Brilliant Ultra Violet, FL Fluidigm, BL BioLegend, BD BD
Biosciences, eBio eBiosciences
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CD14, CD15, CD3 and CD56 markers for the cell
population clustering. We performed a typical immu-
nophenotyping analysis (Fig. 4a) in which first distinct
leukocyte (CD45+) populations are identified, and
subsequently expression of both inhibitory (marked
by a -) and stimulatory (marked by a +) checkpoint
receptors [56] are evaluated on these subsets. Data
demonstrates that T-and NK cell subsets comprise a
large percentage of TILs, and indicates that inhibitory
check point receptors are predominantly co-expressed
by CD56 and CD8 positive cells. Our findings are in
agreement with other published reports [57–59] and
can be used not only in the biomarker discovery, but
also benchmarking responsive patient population in
the clinical settings. While immunophenotyping of
solid tumors is not unique to MC, and has been re-
ported using FC both in the research and clinical set-
tings [19, 60], the maximum number of analytes by
FC still remains well below of total of 39 markers
used in our studies, as well as reported by others
[61], Taking advantage of all the markers in our panel
beyond identifying leukocyte phenotypes we extended
Fig. 2 Detection of cellular subsets in PBMC samples by mass and fluorescent cytometry. a Representative gating scheme identifying major
immune cell populations in PBMCs by FC and MC. Singlet cells, deemed viable by a Live/Dead marker (FC) or DNA intercalator (MC) were used as
the parent population for cell surface marker analysis. Percentage of positive cells on a bivariate plot of CD45 and markers common to both
platforms were compared. Markers included in analysis: CD11b, CD127, CD14, CD15, CD19, CD25, CD27, CD3, CD4, CD86, CD8a, HLA-ABC, HLA-DR,
PD-1 and PD-L1. b Comparison of population percentages quantified by FC and MC. Percentages of cells positive for CD45 and 15 common
markers were quantified by both platforms. Data represents log10 (average) ± standard deviation (SD) (N = 3) of percent positive cells. Correlation
between FC and MC was determined by Pearson Product Moment Correlation (PPMC) (r = 0.96, p < 0.0001)
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this analysis to the tumor cells (Fig. 4b). Sp1 cells were
marked by expression of CD34, CD107a (LAMP-1) and
HLA-ABC, while Sp2 cells expressed CD199 (CCR9), PD-
L2, CTLA, CD56 (NCAM), PD-L1 and PD-L2. Sp1 and Sp2
made up 39.59 and 22.44% of the tumor cells respectively.
These data indicate that analysis of fresh clinical specimens
using high multiplexing capabilities of CyTOF™ can provide
insights into tumor cell microenvironment, thus enabling
in-depth studies of complex interplay between tumor cells
and infiltrating immune cells, and potentially elucidating
novel targets for immunotherapy. This analysis was also ap-
plied to fresh colorectal carcinoma (CRC) specimen
(Additional file 2) with similar findings.
Effects of cryopreservation on cell viability, and lymphoid
and myeloid cell lineages detection in tumor samples
The effects of cryopreservation on clinical specimens
resulting in loss and/or alteration of multiple cell surface
and intracellular marker detection, has long been a
challenge for accurate sample immunophenotyping on
different detection platforms, potentially hindering de-
terminations of immune cell subpopulations relevant to
patient stratification [62]. These changes might be due
to decrease in either receptor expression levels or modi-
fications in epitope conformation rendering these no
longer accessible to detection antibodies. With the emer-
gence of high-multiplexing detection of 50 or more
markers by mass cytometry, the overall effect of cryo-
preservation can be now effectively interrogated on a
single cell level.
In order to determine cryopreservation effects associ-
ated with long-term storage of tumor samples, an immu-
nophenotypic analysis of fresh tumor specimens
immediately after tissue dissociation was performed and
compared to the samples analyzed on day 28 (T1) and
58 (T2) after cryopreservation. For this analysis fresh
primary RCC and CRC were obtained and processed
within 12 h after surgical removal. The tumor specimens
Fig. 3 Comparison of FC and MC detection of immunophenotyping markers in frozen primary tumor samples. a Ratio of percent positive cells
detected by FC over MC for 19 common markers. Correlation between FC and MC was determined by Pearson Product Moment Correlation
(PPMC). b Cell number and viability measurements. Viability and cell number as determined by FC analysis using an amine-reactive dye. Viability
and number of acquired events as determined by MC analysis using 103Rh and 191/193Ir DNA intercalators. Cellular counts are expressed on a log10
scale. Data indicate that the viability and cell number differences acquired using FC and MC were major contributing factors in divergence of
detected cellular frequencies in tumor samples
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were greater than 2.0 g in mass. Dissociated cells were
used for immediate analysis, and remaining cells were
cryopreserved and used in subsequent experiments. 30
to 50 million cells were obtained per tumor sample,
allowing for at least four vials containing 2–3 million
cells per CM formulation to be frozen. Viability and cell
numbers were assessed by Trypan blue exclusion imme-
diately after tumor dissociation and at both recovery
time points (Fig. 5a). Decrease in cell viability upon
cryopreservation was evident for both RCC and CRC
samples (Fig. 5a). The commonly used cryopreservation
medium, CM1, containing 90 FBS and 10% tissue grade
neat DMSO, was the most effective in preserving cell
viability for both tumor types, with approximately 80%
of viable cells for both time points. In contrast, samples
frozen with 90 FBS and 10% of glycerol (CM3) had via-
bility below 60% at both time points for both tumor
types. CM2 formulation contained conditioned media in
which the tumors were stored following excision until
processing, and the viability for both time points was
above 70% at T1 and T2 for both tumor types. Under
this condition, the viability measured for the RCC sam-
ple was 81.8 and 81.1%, while for the CRC samples the
measured viability was 72.2 and 75.0% at T1 and T2 re-
spectively. Because commercial AQIX media is opti-
mized for preservation of cells and tissue biopsies [63], it
is possible that the ability of this media to maintain pH
levels at fluctuating temperatures [64], as well as the tis-
sue specific growth factors secreted by cells while in
transit, are responsible for preserving cellular viability.
CM4, a serum-free, DMSO-free commercial media sup-
plemented with a proprietary cryoprotectant was marked
by a decrease in viability for the CRC sample measuring
values at T1 of 76.7 and T2 of 66.7%. The viability of the
RCC sample as compared to CRC was better with 74.3
viability at T1, and 88.0% at T2.
Although cell viability was best maintained with CM1
media, there still was a significant loss in total cell num-
bers as observed during both recovery time points. For
the RCC sample, close to 90% of cells were lost from T1
to T2 post-freeze thaw time point as compared to other
CM formulations. The CRC sample appeared to be more
stable during cryopreservation, and cell recovery varied
among the different media tested. The greatest decline
in cell recovery from first to second thaw was observed
with CM4, showing a 94% cell loss (Fig. 5a), while total
Fig. 4 MC analysis of expression patterns of immunomodulatory and disease prognostic biomarkers in immune and tumor cell subsets. ViSNE
analysis of fresh renal cell carcinoma performed using single nucleated cells as top level population. A total of 40,000 cells was analyzed and
clustered using the following markers: CD45, CD19, CD11B, CD4, CD8A, CD11C, CD34, CD66B, CD14, CD15, CD3 and CD56. The cells in the ViSNE
map are colored according to the median intensity of expression for markers as identified in the top left corner of each figure. a Immunophenotyping
of CD45+ cells in solid tumor sample. T-cell subsets are identified by expression of CD4 and CD8 markers, B-cells by expression of CD19, NK cell by
CD56+, DC cells by CD11C+, Monocytes CD14+, Neutrophils CD15+, and MDSC by CD15+/CD66B+. Checkpoint regulatory receptors are represented by
inhibitory (PD-1, BTLA, CTLA-4, TIM-3, and TIGIT) and stimulatory (GITR, CD137, CD27) markers on identified cellular subsets. b Immunophenotyping of
CD45- cells in solid tumor sample. Specific subsets (Sp) were identified based on these expression patterns; Sp1: CD34bright, CD107a+, HLA-ABC+, HLA-DRmid.
Sp2: CCR9+, CD56+, CTLA-4+, PD-L1+, PD-L2+
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cell loss measured for other cryomedia formulations was
between 65 and 80%.
In addition to cell viability, we examined cryopreserva-
tion effects on the expression of common cell surface
markers (Fig. 5b). For this analysis, raw median inten-
sities for all surface markers were assessed in the CD45+
cell population. A representation of the different effects
of cryopreservation on surface marker expression is
depicted as histogram overlays (Fig. 5b). Our data indi-
cates that 24 out of 39 analyzed markers show decreased
median intensities upon cryopreservation. The majority
of the markers affected by cryopreservation are those
Fig. 5 Cryopreservation effects on cellular viability and cell number recovery in renal cell carcinoma and colorectal carcinoma. a Viability and cell
number determined by Trypan blue exclusion. For each tumor type 2–3 million cells per vial were frozen and samples were recovered in 10 mL
complete media. Determinations of viable cells/mL are shown on a log10 scale. b Cryopreservation effects on surface marker detection and
cellular subset identification in primary renal cell carcinoma. Comparison between fresh and CM1-cryo preserved renal cell carcinoma samples is
expressed as histogram overlays of surface markers in CD45+ parent population. Percent positive cells as part of CD45+ population associated
with selected cell surface markers are summarized in complementary table. c ViSNE analysis of fresh and cryopreserved renal cell specimen. The
viSNE maps are colored based on median expression of selected cell surface markers, the intensity levels are represented by sliding scale. Equal
sampling totaling 25,000 cells for both fresh and frozen specimens was used in this analysis. Singlet-live cells, as determined by cell length and
cellular nucleation state, were used as the top level population. Clustering was done using the following markers: CD45, CD19, CD11B, CD4, CD8a,
CD11C, CD34, CD66B, CD14, CD15, CD44, CD3, CD56, and CD16. CM1 formulation (T1) was selected for fresh to frozen comparison. Expression of
cell surface markers in upper left corner is represented by ViSNE regions colored in gradient of red. Differences in ViSNE scatter plots between fresh
and frozen specimens directly highlight differences in expression levels of surface markers used for clustering, and are highlighted by red masking
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used to identify cells of myeloid lineage, such as CD11B,
CD14, CD15, CD16, CD66B, CD80, CD86, and CD141.
Additionally CD107a and CD25 expression levels are
also decreased after cryopreservation. Both of these
markers are associated with cellular activation, resulting
in functional phenotypes implicated in anti-tumor re-
sponse [65, 66]. Although most surface markers tested
in this study are affected at varying levels, samples pre-
served in CM1 showed greater median intensities as
compared to other cryomedia formulations (Fig. 5b).
Expression patterns seen with CM3 had the least agree-
ment with fresh samples. These findings are in align-
ment with the viability and cell number recovery
measurements (Fig. 5a). Considering all aspects of cryo-
preservation, these data demonstrate that commonly
used 90 FBS-10% DMSO formulation, although superior
at preserving cellular viability as compared to other CM
formulations, still has detrimental effects on expression
levels of many surface markers.
To further determine if the observed expression level
differences of several cell surface markers between fro-
zen and fresh samples are associated with particular cell
subpopulations, we applied a ViSNE analysis using the
fresh RCC CM1 frozen sample (Fig. 5c). The resulting
scatter plots show differential expression of multiple
markers in fresh and frozen samples, thus altering spatial
relationships of cells as determined by their phenotypes.
While data indicates that Th-cells, Tc-cells and mono-
cytes subpopulations are well identified in frozen cell
preparations as compared to fresh samples, it also clearly
highlights a specific loss of MDSCs as defined by co-
expression of CD66b+ and CD15+, HLA-DRdim and
CD14− phenotype. Similar results have been reported in
whole blood sample analysis [62]. Because MDSCs are
believed to be involved in regulation of tumor progres-
sion [67], preferential decrease in detection of this sub-
population might reduce the value of frozen tumor
samples for biomarker research. In addition to common
cell surface markers, we have evaluated expression of
known immunoregulatory receptors on Th and Tc cell
subsets (Additional file 3). Most noticeably, the median
intensities of PD-1, its ligands PD-L1 and PD-L2, GITR
and Lag-3 are significantly decreased in both T- cell sub-
types upon cryopreservation. The observed decrease in
median intensity ranged from 2- to 5-fold in all frozen
samples, which is in agreement with previous publica-
tion using PBMCs [68]. Our results warrant further
studies in identifying new cryopreservation media suit-
able for preserving multiple cellular phenotypes.
Discussion
The ability to quantify effects of therapeutic intervention
in heterogeneous cell populations and to correlate these
with clinical outcome is of critical importance for the
success of drug discovery and development. However, ef-
ficacy data from preclinical studies using animal models
or immortalized cell lines does not always translate to
clinical efficacy [69, 70], nor does it recapitulate the
complex interactions responsible for cellular homeosta-
sis. Simultaneous and quantitative measurement of mul-
tiple biomarkers that directly reflect cellular functional
status in individual, primary patient cells, is, therefore,
highly desired, particularly in immuno-oncology, where
a deeper understanding of the complex responses of im-
mune cells to tumors can facilitate discovery of new
therapeutics and aid in patient stratification strategies.
Mass cytometry, although relatively new to the field of
single-cell analysis, has attracted significant interest for
its ability to simultaneously profile up to 100 phenotypic
and functional markers, enabling in-depth understand-
ing of biomarker complexity [71, 72].
While several landmark studies have shown proof-of-
concept [25, 43, 73, 74] of the MC analysis, comprehen-
sive comparison to the gold standard of single cell ana-
lysis, flow cytometry, as applied to different samples,
including tumors, is still limited. The initial analysis of
frozen PBMC single donor sample over 9 independent
runs enabled us to systematically evaluate precision and
accuracy of analytical performance of the MC platform.
The results of this study were in agreement with previ-
ously published data [73], and demonstrated that the
major immune subsets constituting PBMCs are consist-
ently detected using MC, with inter-run variability for all
PBMC subpopulations below two-fold difference across
nine runs.
Although we observed significant correlation between
FC and MC using PBMC samples, the agreement be-
tween the two platforms using frozen tumor samples
was variable. A number of factors can be considered to
explain discrepancy for several tumor samples. Our data
indicate that the samples exhibiting substantial discrep-
ancy were marked by significant differences in acquired
cell numbers and differences in viability determinations
between FC and MC. Additionally the use of multiple
panels required for FC, and overall lower sampling effi-
ciencies reported for MC [73] played potential factors
which contributed to variability in detected marker fre-
quencies in both platforms. In contrast, tumor samples
exhibiting significant correlation between FC and MC
analyses had similar detected viability and acquired cell
numbers on either platform. These data indicate that
both FC and MC platforms are sensitive to quality and
quantity of the analyzed samples, specifically evidenced
with the commonly used frozen tumor samples.
To assess applicability of the MC platform for bio-
marker discovery in clinically relevant specimens, a
comprehensive phenotyping analysis of fresh renal car-
cinoma using 39 simultaneous markers, validating
Kadić et al. BMC Immunology  (2017) 18:6 Page 11 of 15
detection of immune cell subtypes and various tumor
cell subpopulations, was performed. The high multiplex-
ing capability of CyTOF™ enabled identification of major
leukocyte populations, as evaluated by the co-expression
of various checkpoint regulators, as well as several
tumor subtypes. For example, we were able to identify
tumor subpopulations marked by presence of CD34bright
cells, potentially representing cancer stem cells (CSC),
implicated in tumor initiation and progression [75].
However given significant heterogeneity reported in
CSCs [76], it is impossible to definitively identify these
cells as CSC without including additional markers
known to be expressed on tumor initiating cells [77] or
performing in-vitro experiments assessing functional
pluripotent responses of these cells [78]. Regardless of
the precise cellular identity of this population, the co-
expression of CD107a (Lysosome Associated Membrane
Protein-1, LAMP1) might suggest a connection to auto-
cytolitic activity of NK cells [79]. We identified add-
itional subpopulations marked by expression of CCR9
which potentially represent a subtype of tumor cells in
the process of migrating to the small intestine where the
CCR9 ligand, CCL25, is expressed [80, 81]. Furthermore,
co-expression of inhibitory molecules CTLA-4, PD-L1
and PD-L2 on these tumor subtypes indicates the com-
plex biology of tumor cells [82], suggesting that targeting
multiple checkpoints expressed in particular tumors
might have an additive therapeutic benefit. The pheno-
typing results of fresh clinical biospecimens confirm that
these samples present a suitable model for understand-
ing cancer pathophysiology.
As the end goal of this study to explore the use of
MC analysis for clinical specimens, we further exam-
ined effect of cryopreservation on colon and renal cell
carcinoma using four commonly used cryomedia for-
mulations. Detrimental effects on both viability and
cellular recovery were apparent using all media for-
mulations, however the traditionally used freezing
media of 90 FBS and 10% DMSO, was superior as
compared to others, possibly due to DMSO’s ability
to penetrate cells better than glycerol [83]. Extensive
publications documenting detrimental effects of cryo-
preservation on cells and in particular embryonic
stem cells [84, 85] could potentially explain the dra-
matic cell loss observed in this study. Because enzym-
atic digestion and mechanical dissociation have been
implicated as the major contributing factors in indu-
cing cellular apoptosis upon freezing [86, 87], similar
effects, as a result of tissue processing and cryo-
preservation, may cause the observed decrease in
DTC cell numbers. Further studies are required to
determine if the observed differences in cryopreserva-
tion and recovery are organ and specimen specific, or
are due to the sample processing methods.
In addition, cryopreservation affected the expression
of many myeloid surface markers, possibly explaining
the lack of detection of MDSC as previously described
in PBMCs [62, 88]. Furthermore the decreased detection
of CD107a and CD25 is particularly concerning as both
markers are used to asses cellular activation states, as
well as identification of CD25+ Treg cells [9], a subset
critical for regulating anti-tumor immune response [89].
Our findings are also in agreement with previously pub-
lished data documenting a damaging cryopreservation
effects on PD-1 and PD-L1 detection in PBMCs [68],
and further extend these results to tumor samples.
Conclusion
In summary, our data suggests that results generated by
MC are comparable to FC for both PBMC and tumor
samples. However, MC analysis offers an improved ability
for multiplexing of up to 39 markers. The obvious advan-
tage of highly multiplexed MC capabilities is exemplified
by the detection of tumor cells expressing markers poten-
tially valuable for diagnosis, prognosis, assessment of
treatment efficacy and patient stratification strategies. As
the sensitivity and throughput are further improved of this
still-developing platform, it is conceivable that MC could
become the primary detection method for interrogation of
complex interactions between tumor and immune sub-
types at real time from clinical biopsies. This can be par-
ticularly critical in developing novel immunomodulatory
therapies which are aimed at overcoming cancer resist-
ance [90–92]. However, our data also cautions to the qual-
ity of frozen specimens used for biomarker discovery. The
loss of specific subpopulations, particularly of those impli-
cated in tumor-related biology, presents a challenge for
using frozen clinical specimens for immunomodulatory
biomarker studies. While additional studies extending to
multiple tumors from various organ sources are needed to
further corroborate these findings, the present study with
renal and colon carcinomas supports further investment
in developing more suitable clinical sample handling.
Additional files
Additional file 1: Supplementary Table 1 provides a list of MC
antibodies used for immunophenotyping of fresh and frozen RCC and
CRC samples. (DOCX 75 kb)
Additional file 2: Supplemental data for Fig. 4 presents expression
patterns of immunomodulatory and disease prognostic biomarkers
monitored on immune and tumor cell subsets in fresh CRC as delineated
by MC analysis. ViSNE analysis of fresh CRC performed using singlet live
cells as top level population. A total of 10,902 events were sampled with
cellular clustering performed using CD45, CD3, CD4, CD8a, CD20, CD56,
CD11B, CD14, CD11C, and CD16 cell surface markers. Median expression
levels of the markers listed in upper right corner of each plot is used for
identification of cellular subtypes present in this sample. Expression of
CD194 and CD183 on CD45− cells are considered as potential clinical
biomarkers, correlating with an advanced disease state and associating
Kadić et al. BMC Immunology  (2017) 18:6 Page 12 of 15
with significantly poorer prognosis and an increased metastatic potential
of colorectal cancers. (DOCX 785 kb)
Additional file 3: Supplemental data for Fig. 5b provides additional
information on cryopreservation effects on IMR expression in primary
RCC samples. The data is depicted as histogram overlays of median
intensities for selected markers as expressed in Th and Tc-cell subtypes.
(DOCX 312 kb)
Abbreviations
Ab: Antibody; ACK: Ammonium-chloride-potassium; AML: Acute myeloid leukemia;
BSA: Bovine Serum Albumin; BTLA: B-and T-lymphocyte attenuator; CCL25: C-C
motif chemokine ligand 25.; CCR9: C-C motif chemokine receptor 9;
CM: Cryopreservation medium; CRC: Colorectal carcinoma; CSC: Cancer stem cells;
CSM: Cell-staining-medium; CTLA-4: Cytotoxic T-lymphocyte antigen-4;
CyTOF: Cytometry by time-of-flight; DC: Dendritic cells; DMSO: Dimethyl sulfoxide;
DPBS: Dulbecco’s Phosphate-buffered Saline; DTC: Dissociated tumor cells; FBS: Fetal
bovine serum; FC: Fluorescent cytometry (flow cytometry); FMM: Flourescent minus
multiple; GITR: Glucocorticoid-induced TNFR-related protein; HTS: High-throughput
sampler; IMR: Immunoregulatory receptors; Lag-3: Lymphocyte-activation gene 3;
LAMP-1: Lysosomal-associated membrane protein 1; MC: Mass cytometry;
MDSC: Myeloid derived suppressor cells; MMM: Metal minus multiple; MS: Mass
spectrometry; NAT: Normal adjacent tissue; NCAM: Neural cell adhesion molecule;
NK-cells: Natural-killer cells; PBMC: Peripheral blood mononuclear cells; PD-
1: Programmed cell death-1; PDL-1: Programmed cell death ligand-1; PDL-
2: Programmed cell death ligand 2; PPMC: Pearson product moment correlation;
RBC: Red blood cells; RCC: Renal cell carcinoma; RPMI medium: Roswell Park
Memorial Institute medium; RT: Room temperature; Sp: Subpopulation; T1 and
T2: Time point 1 and time point 2; Tc: T-cytotoxic cells; Th: T-helper cells; TIL: Tumor





Availability of data and materials
The data supporting the conclusions of this article are included within the article. In
addition, the raw data involving commercially sourced samples (PBMCs and frozen
DTCs) are available on Cytobank.org (https://merck.cytobank.org/cytobank/
experiments/11118+), while datasets involving fresh tumor samples analyzed
during the current study can be made available from the corresponding author on
reasonable request.
Authors’ contributions
EK was instrumental in conception, design and carrying out all mass cytometry
experiments, including data analysis and elucidation, and was a major
contributor to manuscript preparation. RJM performed all flow cytometry
experiments, data analysis and interpretation, as well as manuscript editing. YH
maintained CyTOF platform, performed QC and calibration experiments, and
executed on sample acquisition. AC has been instrumental at the initial stages
of setting up CyTOF platform, guiding development of detection methods, and
manuscript editing. IK provided scientific guidance to experimental design and
data analysis, and was a major contributor to manuscript preparation. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
Fresh human tumor specimens were properly collected with all necessary
approvals, consents and/or authorizations for the collection, use and/or
transfer of such human tissues through Neurologica Cognitiva Research LLC
DBA Boston Biosource (Newton, MA).
Author details
1Department of Pharmacology, Cellular Pharmacology, Merck and Co. Inc, 33
Avenue Louis Pasteur, Boston 02115, MA, USA. 2Department of
Biology-Discovery, Immunooncology, Merck and Co. Inc, Boston, MA, USA.
3Department of Chemistry, Capabilities Enhancement, Merck and Co. Inc,
Boston, MA, USA.
Received: 18 July 2016 Accepted: 29 January 2017
References
1. De Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune
system during cancer development. Nat Rev Cancer. 2006;6:24–37.
2. Parish CR. Cancer immunotherapy: the past, the present and the future*.
Immunol Cell Biol. 2003;81:106–13.
3. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and
tumor responses with lambrolizumab (anti-PD-1) in Melanoma. N Engl J
Med. 2013;369:134–44.
4. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;
341:1192–8.
5. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al.
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with
metastatic melanoma. Clin Cancer Res. 2012;18:2039–47.
6. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-
programmed-death-receptor-1 treatment with pembrolizumab in
ipilimumab-refractory advanced melanoma: a randomised dose-comparison
cohort of a phase 1 trial. Lancet. 2014;384:1109–17.
7. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell
surveillance and therapy of cancer. Nat Rev Cancer. 2002;2:850–61.
8. Domogala A, Madrigal JA, Saudemont A. Natural killer cell immunotherapy:
from bench to bedside. Front Immunol. 2015;6:264.
9. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, Harrop R, et al.
CD4 + CD25 + FOXP3+ regulatory T cells suppress anti-tumor immune
responses in patients with colorectal cancer. Plos One. 2006;1:e129.
10. Mak IW, Evaniew N, Ghert M. Lost in translation: animal models and clinical
trials in cancer treatment. Am J Transl Res. 2014;6:114–8.
11. Peterson JK, Houghton PJ. Integrating pharmacology and in vivo cancer models in
preclinical and clinical drug development. Eur J Cancer. 2004;40:837–44.
12. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI cancer biomarkers
collaborative consensus report: advancing the use of biomarkers in cancer
drug development. Clin Cancer Res. 2010;16:3299–318.
13. Goulart BHL, Clark JW, Pien HH, Roberts TG, Finkelstein SN, Chabner BA.
Trends in the use and role of biomarkers in phase I oncology trials. Clin
Cancer Res. 2007;13:6719–26.
14. Zips D, Thames HD, Baumann M. New anticancer agents: in vitro and in
vivo evaluation. In Vivo. 2005;19:1–7.
15. Hayashi K, Masuda S, Kimura H. Analyzing global trends of biomarker use in
drug interventional clinical studies. Drug Discov Ther. 2012;6:102–7.
16. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer
immunotherapy. Mol Cancer Ther. 2015;14:847–56.
17. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al.
Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J
Med. 2015;372:2018–28.
18. Orfao A, Schmitz G, Brando B, Ruiz-Arguelles A, Basso G, Braylan R, et al.
Clinically useful information provided by the flow cytometric
immunophenotyping of hematological malignancies: current status and
future directions. Clin Chem. 1999;45:1708–17.
19. Corver WE, Cornelisse CJ. Flow cytometry of human solid tumours: clinical
and research applications. Diagn Pathol. 2002;8:249–67.
20. Williams DM, O’Connor S, Grant JW, Marcus RE, Broadbent V. Rapid diagnosis
of malignancy using flow cytometry. Arch Dis Child. 1993;68:393–8.
21. Baumgarth N, Roederer M. A practical approach to multicolor flow
cytometry for immunophenotyping. J Immunol Methods. 2000;243:77–97.
22. Perfetto SP, Chattopadhyay PK, Roederer M. Seventeen-colour flow cytometry:
unravelling the immune system. Nat Rev Immunol. 2004;4:648–55.
23. Miranda-Lorenzo I, Dorado J, Lonardo E, Alcala S, Serrano AG, Clausell-
Tormos J, et al. Intracellular autofluorescence: a biomarker for epithelial
cancer stem cells. Nat Method. 2014;11:1161–9.
24. Bandura DR, Baranov VI, Ornatsky OI, Antonov A, Kinach R, Lou X, et al. Mass
cytometry: technique for real time single cell multitarget immunoassay
Kadić et al. BMC Immunology  (2017) 18:6 Page 13 of 15
based on inductively coupled plasma time-of-flight mass spectrometry. Anal
Chem. 2009;81:6813–22.
25. Di Palma S, Bodenmiller B. Unraveling cell populations in tumors by single-
cell mass cytometry. Curr Opin Biotechnol. 2015;31:122–9.
26. Bjornson ZB, Nolan GP, Fantl WJ. Single-cell mass cytometry for analysis of
immune system functional states. Curr Opin Immunol. 2013;25:484–94.
27. Ornatsky O, Bandura D, Baranov V, Nitz M, Winnik MA, Tanner S. Highly
multiparametric analysis by mass cytometry. J Immunol Methods. 2010;361:1–20.
28. Bodenmiller B, Zunder ER, Finck R, Chen TJ, Savig ES, Bruggner RV, et al.
Multiplexed mass cytometry profiling of cellular states perturbed by small-
molecule regulators. Nat Biotechnol. 2012;30:858–67.
29. Behbehani GK, Bendall SC, Clutter MR, Fantl WJ, Nolan GP. Single-cell mass
cytometry adapted to measurements of the cell cycle. Cytometry. 2012;81A:
552–66.
30. Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan
OC, et al. Genetic and environmental determinants of human NK cell
diversity revealed by mass cytometry. Sci Transl Med. 2013;5:208ra145.
31. Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, et al. Single-cell mass
cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-
mutated AML stem/progenitor cells. Cytometry. 2015;87:346–56.
32. Wang L, Abbasi F, Ornatsky O, Cole KD, Misakian M, Gaigalas AK, et al. Human CD4
+ lymphocytes for antigen quantification: characterization using conventional flow
cytometry and mass cytometry. Cytometry. 2012;81A:567–75.
33. Nicholas KJ, Greenplate AR, Flaherty DK, Matlock BK, Juan JS, Smith RM, et
al. Multiparameter analysis of stimulated human peripheral blood
mononuclear cells: a comparison of mass and fluorescence cytometry.
Cytometry. 2016;89:271–80.
34. Marina Prilutskaya DS, Pustilnik J, Balukova O, Dyakova N, Fenik L. Quality
Bio-specimens for novel biomarker discovery. Transl Med. 2012;S1:2–5.
35. Grizzle WE, Bell WC, Sexton KC. Issues in collecting, processing and storing
human tissues and associated information to support biomedical research.
Cancer Biomark. 2010;9:531–49.
36. Kushnir MM. Are samples in your freezer still good for biomarker discovery?
Am J Clin Pathol. 2013;140:287–8.
37. Guibert EE, Petrenko AY, Balaban CL, Somov AY, Rodriguez JV, Fuller BJ.
Organ preservation: current concepts and new strategies for the next
decade. Transfus Med Hemtother. 2011;38:125–42.
38. Schroy CB, Todd P. A simple method for freezing and thawing cultured
cells. Tissue Culture Assoc Manual. 1976;2:309–10.
39. Leipold MD, Maecker HT. Mass cytometry: protocol for daily tuning and
running cell samples on a CyTOF mass cytometer JoVE. J Vis Exp. 2012;4398.
40. Chen TJ, Kotecha N. Cytobank: Providing an Analytics Platform for
Community Cytometry Data Analysis and Collaboration. Curr Top Microbiol
Immunol. 2014;377:127–57.
41. Zunder ER, Finck R, Behbehani GK, Amir ED, Krishnaswamy S, Gonzalez VD, et
al. Palladium-based mass tag cell barcoding with a doublet-filtering scheme
and single-cell deconvolution algorithm. Nat Protoc. 2015;10:316–33.
42. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping
for the human immunology project. Nat Rev Immunol. 2012;12:191–200.
43. Amir ED, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al.
viSNE enables visualization of high dimensional single-cell data and reveals
phenotypic heterogeneity of leukemia. Nat Biotechnol. 2013;31:545–52.
44. van der Maaten L, Hinton G. Visualizing data using t-SNE. J Mach Learn Res.
2008;9:2579–605.
45. Bendall SC, Nolan GP, Roederer M, Chattopadhyay PK. A deep profiler’s
guide to cytometry. Trend Immunol. 2012;33:323–32.
46. Allan AL, Keeney M. Circulating tumor cell analysis: technical and statistical
considerations for application to the clinic. J Oncol. 2010;2010:426218.
47. Majonis D, Ornatsky O, Kinach R, Winnik MA. Curious results with palladium- and
platinum-carrying polymers in mass cytometry bioassays and an unexpected
application as a dead cell stain. Biomacromolecules. 2011;12:3997–4010.
48. Wersto RP, Chrest FJ, Leary JF, Morris C, Stetler-Stevenson M, Gabrielson
E. Doublet discrimination in DNA cell-cycle analysis. Cytometry. 2001;46:
296–306.
49. Perfetto SP, Chattopadhyay PK, Lamoreaux L, Nguyen R, Ambrozak D, Koup
RA, et al. Amine-reactive dyes for dead cell discrimination in fixed samples.
Curr Protoc Cytom. 2010;9:34. CHAPTER:Unit.
50. Ornatsky OI, Lou X, Nitz M, Sheldrick WS, Baranov VI, Bandura DR, et al.
Study of cell antigens and intracellular DNA by identification of element-
containing labels and metallointercalators using inductively coupled plasma
mass spectrometry. Anal Chem. 2008;80:2539–47.
51. Lorent JH, Quetin-Leclercq J, Mingeot-Leclercq M-P. The amphiphilic nature
of saponins and their effects on artificial and biological membranes and
potential consequences for red blood and cancer cells. Org Biomol Chem.
2014;12:8803–22.
52. Shenkin M, Babu R, Maiese R. Accurate assessment of cell count and
viability with a flow cytometer. Cytometry B Clin Cytom. 2007;72:427–32.
53. Kummrow A, Frankowski M, Bock N, Werner C, Dziekan T, Neukammer J.
Quantitative assessment of cell viability based on flow cytometry and
microscopy. Cytometry A. 2013;83:197–204.
54. Behbehani GK, Samusik N, Bjornson ZB, Fantl WJ, Medeiros BC, Nolan GP.
Mass cytometric functional profiling of acute myeloid leukemia defines cell-
cycle and immunophenotypic properties that correlate with known
responses to therapy. Canc Discov. 2015;5:988–1003.
55. Atkuri KR, Stevens JC, Neubert H. Mass cytometry: a highly multiplexed
single-cell technology for advancing drug development. Drug Metab
Dispos. 2015;43:227–33.
56. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z
of negative checkpoint regulators. Front Immunol. 2015;6:418.
57. Geissler K, Fornara P, Lautenschläger C, Holzhausen H-J, Seliger B, Riemann
D. Immune signature of tumor infiltrating immune cells in renal cancer.
Oncoimmunol. 2015;4(1), e985082.
58. Schleypen JS, von Geldern M, Weiß EH, Kotzias N, Rohrmann K, Schendel DJ,
et al. Renal cell carcinoma-infiltrating natural killer cells express differential
repertoires of activating and inhibitory receptors and are inhibited by
specific HLA class I allotypes. Int J Cancer. 2003;106:905–12.
59. Donskov F. Immunomonitoring and prognostic relevance of neutrophils in
clinical trials. Sem Cancer Biol. 2013;23:200–7.
60. Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, et al. Fine needle
aspirate flow cytometric phenotyping characterizes immunosuppressive
nature of the mesothelioma microenvironment. Sci Report. 2016;6:31745.
61. Nalin L, Deon BD, Allison RG, Bret CM, Jonathan ML, Justine S, Rondi MK,
Jay AW, Akshitkumar MM, Kyle DW, Reid CT, Pierre PM, Mary AH, Mark CK,
Lola BC, Rebecca AI, Jonathan MI. Single cell analysis of human tissues
and solid tumors with mass cytometry. Cytometry B Clin Cytom. 2017;92:
68–78.
62. Kotsakis A, Harasymczuk M, Schilling B, Georgoulias V, Argiris A, Whiteside
TL. Myeloid-derived suppressor cell measurements in fresh and
cryopreserved blood samples. J Immunol Methods. 2012;381:14–22.
63. Ozeki T, Kwon MH, Gu J, Collins MJ, Brassil JM, Miller MB, et al. Heart
preservation using continuous ex vivo perfusion improves viability and
functional recovery. Circ J. 2007;71:153–9.
64. Kay MD, Hosgood SA, Harper SJF, Bagul A, Waller HL, Rees D, et al. Static
normothermic preservation of renal allografts using a novel nonphosphate
buffered preservation solution. Transpl Int. 2007;20:88–92.
65. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the
identification of natural killer cell activity. J Immunol Methods. 2004;294:
15–22.
66. Caruso A, Licenziati S, Corulli M, Canaris AD, De Francesco MA,
Fiorentini S, et al. Flow cytometric analysis of activation markers on
stimulated T cells and their correlation with cell proliferation.
Cytometry. 1997;27:71–6.
67. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of
the immune system. Nat Rev Immunol. 2009;9:162–74.
68. Campbell DE, Tustin NB, Riedel E, Tustin R, Taylor J, Murray J, et al.
Cryopreservation decreases receptor PD-1 and ligand PD-L1 coinhibitory
expression on peripheral blood mononuclear cell-derived T cells and
monocytes. Clin Vaccine Immunol. 2009;16:1648–53.
69. Crowley Jr WF. Translation of basic research into useful treatments: how
often does it occur? Am J Med. 2003;114:503–5.
70. Gillet J-P, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al.
Redefining the relevance of established cancer cell lines to the study of
mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S
A. 2011;108:18708–13.
71. Bendall SC, Nolan GP. From single cells to deep phenotypes in cancer. Nat
Biotechnol. 2012;30:639–47.
72. Ferrell PB, Diggins KE, Polikowsky HG, Irish JM. Mass cytometry of acute
myeloid leukemia captures early therapy response in rare cell subsets.
Blood. 2014;124:2381.
73. Yao Y, Liu R, Shin MS, Trentalange M, Allore H, Nassar A, et al. CyTOF
supports efficient detection of immune cell subsets from small samples. J
Immunol Methods. 2014;415:1–5.
Kadić et al. BMC Immunology  (2017) 18:6 Page 14 of 15
74. Wistuba-Hamprecht K, Martens A, Weide B, Teng KWW, Zelba H, Guffart E,
et al. Establishing High Dimensional Immune Signatures from Peripheral
Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma
Patients. J Immunol. 2017;198:927.
75. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;
355:1253–61.
76. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell
Res. 2012;22:457–72.
77. Bussolati B, Brossa A, Camussi G, Bussolati B, Brossa A, Camussi G. Resident
Stem Cells and Renal Carcinoma, Resident Stem Cells and Renal Carcinoma.
Int J Neph. 2011;2011:286985.
78. Lucarelli G, Galleggiante V, Rutigliano M, Vavallo A, Ditonno P, Battaglia M.
Isolation and characterization of cancer stem cells in renal cell carcinoma.
Urologia. 2015;82:46–53.
79. Cohnen A, Chiang SC, Stojanovic A, Schmidt H, Claus M, Saftig P, et al.
Surface CD107a/LAMP-1 protects natural killer cells from degranulation-
associated damage. Blood. 2013;122:1411–8.
80. Amersi FF, Terando AM, Goto Y, Scolyer RA, Thompson JF, Tran AN, et al.
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential
metastasis to the small intestine. Clin Cancer Res. 2008;14:638–45.
81. Gorski RL, Jalil SA, Razick M, Jalil AA. An obscure cause of gastrointestinal
bleeding: renal cell carcinoma metastasis to the small bowel. Int J Sur Case
Rep. 2015;15:130–2.
82. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-
inhibition. Nat Rev Immunol. 2013;13:227–42.
83. Farshad A, Khalili B, Fazeli P. The effect of different concentrations of
glycerol and DMSO on viability of markhoz goat spermatozoa during
different freezing temperatures steps. Pak J Biol Sci. 2009;12:239–45.
84. Bissoyi A, Nayak B, Pramanik K, Sarangi SK. Targeting cryopreservation-
induced cell death: a review. Biopreserv Biobank. 2014;12:23–34.
85. Heng BC, Ye CP, Liu H, Toh WS, Rufaihah AJ, Yang Z, et al. Loss of viability
during freeze-thaw of intact and adherent human embryonic stem cells
with conventional slow-cooling protocols is predominantly due to
apoptosis rather than cellular necrosis. J Biomed Sci. 2006;13:433–45.
86. Xu X, Cowley S, Flaim CJ, James W, Seymour L, Cui Z. The roles of apoptotic
pathways in the low recovery rate after cryopreservation of dissociated
human embryonic stem cells. Biotechnol Prog. 2010;26:827–37.
87. Ohgushi M, Matsumura M, Eiraku M, Murakami K, Aramaki T, Nishiyama A, et
al. Molecular pathway and cell state responsible for dissociation-induced
apoptosis in human pluripotent stem cells. Cell Stem Cell. 2010;7:225–39.
88. Trellakis S, Bruderek K, Hütte J, Elian M, Hoffmann TK, Lang S, et al.
Granulocytic myeloid-derived suppressor cells are cryosensitive and their
frequency does not correlate with serum concentrations of colony-
stimulating factors in head and neck cancer. I Immunity. 2013;19:328–36.
89. Nishikawa H, Sakaguchi S. Regulatory T cells in tumor immunity. Int J
Cancer. 2010;127:759–67.
90. Ishida T, Ueda R. CCR4 as a novel molecular target for immunotherapy of
cancer. Cancer Sci. 2006;97:1139–46.
91. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on
tumor cells in the escape from host immune system and tumor immunotherapy
by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–7.
92. Van Raemdonck K, Van den Steen PE, Liekens S, Van Damme J, Struyf S.
CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev. 2015;26:
311–27.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Kadić et al. BMC Immunology  (2017) 18:6 Page 15 of 15
